Biomarkers may be a key foundation for the precision medicine of the future. In this article, we review current knowledge regarding biomarkers in difficult-to-treat asthma and their ability to guide the use of both conventional asthma therapies and novel (targeted) therapies. Biomarkers (as measured by tests including prednisolone and cortisol assays and the fractional exhaled nitric oxide (NO) suppression test) show promise in the assessment and management of nonadherence to inhaled and oral corticosteroids. Multiple markers of type 2 inflammation have been developed, including eosinophils in sputum and blood, exhaled NO, serum IgE and periostin. Although these show potential in guiding the selection of novel interventions for refractory type 2 inflammation in asthma, and in determining if the desired response is being achieved, it is becoming clear that different biomarkers reflect distinct components of the complex type 2 inflammatory pathways. Less progress has been made in identifying biomarkers for use in difficult-to-treat asthma that is not associated with type 2 inflammation. The future is likely to see further biomarker discovery, direct measurements of individual cytokines rather than surrogates of their activity and the increasing use of biomarkers in combination. If the promise of biomarkers is to be fulfilled, they will need to provide useful information that aids clinical decision-making, rather than being 'just another test' for clinicians to order.
INTRODUCTION
In an era of precision medicine, there is great interest in identifying and characterizing biomarkers in asthma. The need is greatest in those with difficult-to-treat asthma, in whom a uniform treatment approach involving the prescription of ever higher doses of inhaled corticosteroids (ICSs) and long-acting bronchodilators may not provide adequate symptom control and exacerbation risk reduction. Potential uses of biomarkers in difficult-to-treat asthma include measuring and improving adherence to conventional therapy, optimizing existing treatments, guiding the selection of novel (targeted) therapies and assessing treatment responses (Fig. 1 ). An ideal biomarker should be sensitive and specific, easily and reproducibly measured and provide biologically relevant information that aids clinical decision-making. While many biomarkers are currently being investigated in large clinical trials, few if any have yet found a place in clinical management.
In this article, we review the literature on biomarkers in asthma, their potential to identify and manage non-adherence, to assist in the optimization of conventional therapy and to guide the use of targeted therapies.
ADHERENCE TO CONVENTIONAL THERAPY IN DIFFICULT-TO-TREAT ASTHMA
Up to 20% of patients with asthma do not achieve an acceptable level of control despite being prescribed high-dose anti-inflammatory and bronchodilator therapy, and are referred to as having 'difficult-to-treat' or 'difficult asthma'.
1,2 Difficult-to-treat asthma is NOT a diagnosis but is an 'umbrella term', describing a clinical problem requiring careful multidisciplinary assessment. In many cases, after detailed systematic evaluation, a coexistent problem is identified, either alone (misdiagnosis) or together with mild/moderate asthma, and when this is effectively managed, symptoms can be controlled. 3 However, some patients within this wider difficultto-treat asthma group have 'severe asthma' which cannot be controlled with currently available treatments. The current definition of severe asthma requires highdose treatment (high-dose ICS plus second controller for the previous year or systemic corticosteroids ≥50% of the previous year) to either maintain asthma control or which fails to achieve control. 4 Uncontrolled asthma is defined as persisting asthma symptoms, frequent severe exacerbations requiring ≥2 bursts of systemic corticosteroids (or a hospitalization) in the previous year or persistent airflow limitation. 4 Controlled asthma that worsens on tapering of high-dose corticosteroid treatment or additional biological therapy also fits into the category of severe disease. Importantly, the term severe asthma should be reserved for patients with asthma in whom alternative diagnoses have been excluded, adherence with treatment has been checked, co-morbidities have been treated and trigger factors have been removed (where possible).
The challenge of non-adherence to maintenance treatment is prevalent in difficult-to-treat asthma, particularly with ICS and oral corticosteroid (OCS) treatment. [5] [6] [7] In a Belfast study, which examined adherence in 182 patients with difficult-to-treat asthma, 35% had filled <50% of their prescriptions for inhaled combination therapy and 88% admitted low adherence after initial denial. 5 Low adherence was more common in females and was associated with recurrent hospital admissions and use of nebulized bronchodilators. In a Leicester study, 65 .2% of patients on ICS and 60.1% on long-acting β 2 agonists (LABAs) had <80% prescription filling. 6 Patients with low adherence had lower post-bronchodilator forced expiratory volume in 1 s (FEV 1 ), were more likely to have been ventilated for asthma and had higher sputum eosinophils. In a paediatric study from London, prescription filling was assessed as part of a home visit 8 with 30% of children filling prescriptions for <50% of inhaled maintenance therapy; medication issues encompassing adherence, an unsuitable device or poor technique were felt to contribute to poor control in 34 children (48%). The situation is similar for OCS adherence. In the Belfast study, of 51 patients, 49% were found to be non-adherent to prednisolone using a cortisol/prednisolone assay; again patients only admitted low adherence when 'confronted' with objective measurements. 5 In a London study of 28 adult asthmatic patients, 32% of subjects were prescribed ≥15 mg of prednisolone per day, had either nondetectable prednisolone or non-suppression of cortisol. 9 In the Leicester study, using prescription records alone, 26% had low adherence with oral prednisolone. 6 Of note, many of these non-adherent difficult-to-control asthmatic patients are referred from other specialist physicians (Belfast study, 37%; London Paediatric and Adult studies, 100%) suggesting that this problem is not routinely identified in specialist care. This poor identification of non-adherence in routine clinical practice leads to poor healthcare outcome and death, and a recent systematic review identified that adherence to asthma controller therapy was generally low and that higher levels of adherence were associated with a reduced risk of severe asthma exacerbations. 10 In addition, it can result in patients being inappropriately labelled as having 'severe' disease, with the potential for inappropriate escalation to OCS or biological therapies.
How might biomarkers be used to identify and manage non-adherence?
The data available support prednisolone assays, like theophylline assays, becoming routinely available in dedicated Difficult Asthma Services to allow objective assessment of adherence with prednisolone and this could be extended to other OCS. In addition, 'biomarker-based' assessment of ICS response using fractional exhaled nitric oxide (FeNO) may help to identify patients with difficult-to-control asthma, who should achieve good asthma control with better adherence to standard treatment and without escalation to the novel expensive biological therapies. 11 The 'FeNO suppression test' harnesses the fact that in subjects who are ICS responsive, there is a rapid reduction of FeNO when ICS are taken and this is evident within 7 days of directly observed ICS (DOICS) treatment (Fig. 2) . In contrast, subjects who are relatively ICS resistant do not have the same level of reduction and the test can potentially stratify patients with severe asthma into subjects who require further input into adherence and 12 Key challenges going forward will be to ensure widespread implementation of strategies to identify and manage non-adherence effectively in this patient group. 13 However, many producers of ICS/LABA combination therapies have now partnered with remote monitoring technology companies and when these technologies are aligned with biomarker profiling, in the future, the ability to identify and influence poor adherence with corticosteroid treatment will be substantially advanced.
TYPE 2 BIOMARKERS
Most types of asthma involve an inflammatory component. 14, 15 The use of inflammatory biomarkers to guide asthma therapy was first proposed in the 1950s, when the presence of elevated sputum and blood eosinophils was suggested to correlate with corticosteroid responsiveness. 16 Peripheral and pulmonary eosinophilia prompted the discovery in asthma of elevated T helper type 2 (Th2) lymphocytes in circulation and airway tissue that secrete the cytokines IL-4, IL-5 and IL-13. 17, 18 These cytokines underpin type 2 immune responses which are typically associated with increased IgE production, allergic inflammation, eosinophilia and are involved in helminth defence. Alternative sources of Th2-related cytokines include basophils, mast cells and group 2 innate lymphoid cells which are elevated in the circulation and airways of asthmatic patients and could drive corticosteroid-resistant type 2 inflammation in severe asthma. [19] [20] [21] Asthma associated with elevated type 2 immune responses is often termed type 2 asthma, and this form of asthma is best understood from the perspective of biomarkers and their role in defining treatment.
IL-5 drives eosinophil differentiation and maturation in the bone marrow as well as recruitment and activation at sites of allergic inflammation. 22 IL-5 is increased in luminal and bronchial compartments in the asthmatic lung, is induced by allergen challenge and correlates with clinical features. In milder forms of asthma, IL-5 is suppressed by corticosteroid treatment; however, IL-5 remains elevated in severe asthma and thus could contribute to the severe eosinophilic phenotype. 23 Recent clinical trials with biologics targeting IL-5 have confirmed the role of IL-5 in driving systemic and pulmonary eosinophilia in severe asthma (see below). Measurement of IL-5 in sputum or serum could potentially be of clinical use in identifying type 2 asthma, although this has been limited in sputum in part due to enzymatic degradation. 24 Recently developed technologies hold promises for the detection of minute concentrations of type 2 cytokines in circulation, although this requires further validation. 25 Sputum eosinophilia is present in one third to half of mild-tomoderate asthmatic patients and predicts clinically beneficial responses to ICS. 14, [26] [27] [28] Despite this, sputum eosinophilia is elevated in a similar proportion of severe asthmatic patients treated with high-dose ICS 29 ; however, as discussed above the issue of adherence is not well characterized in these studies. Sputum induction and analysis is technically challenging and thus surrogate biomarkers for airway eosinophilia have been sought. Chief amongst these is peripheral blood eosinophil (PBE) count, which correlates with sputum eosinophilia and airway type 2 cytokine expression and predicts corticosteroid response. 21, 30 Measurement of IL-4 and IL-13 proteins in the airways and circulation has also been limited by insufficient assay sensitivity. Measurement of elevated IL-4, IL-5 and IL-13 mRNA was reported in 70% of asthmatic sputum samples, indicating that reliance on conventional sputum and PBE counts might underestimate the number of patients with type 2 asthma. 31 Woodruff et al. identified an IL-4/IL-13-induced epithelial gene signature of periostin, chloride channel accessory 1 -(CLCA1) and serpinB2 that was upregulated in airway epithelial cells from asthmatic patients. 32 The type 2 epithelial gene signature is present in approximately half of steroid-naïve asthmatic patients, correlates with serum IgE, PBE and airway eosinophilia and is rapidly suppressed by ICS. 33 Recent transcriptomic analysis of epithelial brushings suggests that epithelial gene profiling could be useful for phenotyping severe asthmatic patients. 34 Confounding factors such as differential effects of add-on treatments (e.g. macrolides) on the type 2 epithelial gene signature should be noted and explored further. 35 Importantly, periostin protein is detectable in serum and is elevated in a subset of severe asthmatic patients correlating with sputum and airway mucosal eosinophils. 36 The correlation of serum periostin with sputum eosinophilia in asthma was recently confirmed, although serum periostin did not compare favourably with PBE count as a predictor of airway eosinophilia, potentially reflecting the distinct inflammatory signalling mechanisms that drive periostin production versus systemic and airway eosinophilia. 37 Another type 2 biomarker that is linked to IL-4/IL-13-mediated airway inflammation is FeNO. 21 IL-4/IL-13 can increase epithelial NO production through increased expression of inducible NO synthase (NOS), and epithelial NO production may underpin variations in FeNO measurement. 38 As discussed above, in nonsevere asthma, FeNO is a corticosteroid-responsive biomarker and can predict ICS responsiveness. [39] [40] [41] Elevated FeNO in severe asthma can be a marker of poor adherence, but may also reflect refractory airway inflammation. Confirming the presence of truly refractory inflammation may involve DOICS treatment, as discussed in relation to the FeNO suppression test (see above and Fig. 2 ). Compared with other type 2 biomarkers, FeNO shows relatively poor correlation with airway eosinophilia, particularly in severe asthma. 42, 43 Furthermore, a large cross-sectional study concluded that FeNO and PBE associate independently with increased wheeze and asthma exacerbations. 44 Simultaneous elevation of both FeNO and PBE is associated with a higher prevalence of poor asthma control and a higher degree of airway hyper-responsiveness than is seen in individuals with elevation of only FeNO or PBE. 45 Similarly, recent findings indicate that the combination of FeNO, PBE and serum periostin together identifies exacerbation risk better than using these biomarkers in isolation. 12 In sum, sputum eosinophilia, elevated PBE count, elevated FeNO and serum periostin are present in a subset of asthmatic patients and correlate with beneficial responses to ICS in mild forms of asthma. In severe asthma, these type 2 inflammatory markers have individually been associated with more frequent exacerbations, which has been a guiding principle of clinical trial study design for type 2 targeting biologics. 40, 42, 46, 47 Clinical studies, along with results from type 2 targeting biologics (see below), suggest that individual type 2 biomarkers may provide unique information relating to asthma phenotype and further studies are required to delineate their best use in combination.
BIOMARKER-BASED OPTIMIZATION OF CONVENTIONAL THERAPY
In conventional asthma management guidelines, adjustment of anti-inflammatory (including corticosteroids) and bronchodilator therapies is made according to patient's clinical symptoms, spirometry and rescue medication use. The presence of sputum eosinophilia correlates with beneficial corticosteroid responses in asthma. 48 A trial of 68 moderate-to-severe asthmatic patients demonstrated that ICS dose adjustment to maintain sputum eosinophils below 3% resulted in suppression of airway eosinophilia, reduced asthma exacerbations and improved bronchial hyperresponsiveness compared with conventional management. 27 Overall, the mean dose of ICS at completion of the study did not differ between sputum-and guideline-based management, although in the sputumbased group this reflected both successful decrease of ICS dose in non-eosinophilic patients and effective increases in ICS dose in the eosinophilic subgroup. Two further studies, with 102 mild-to-severe 49 and 55 moderate-to-severe 50 asthmatic patients, reached similar conclusions, albeit using different sputum eosinophil thresholds in the ICS adjustment algorithm (2% and 8%, respectively). Of note Jayaram et al. demonstrated that whilst sputum-based management reduced exacerbations associated with eosinophilic airway inflammation, exacerbations associated with noneosinophilic inflammation were unaffected. 49 These studies established the important concept that treatment-responsive biomarker-based management strategies could provide benefit in moderate-to-severe asthma populations.
As discussed above, PBEs are useful surrogate markers for airway eosinophilia in asthma, in particular in the context of a non-specialist clinical setting. Thus, anti-inflammatory treatment adjustment algorithms based on PBE levels could have similar success to sputum-based management and be more broadly applicable. In a small proof-of-principle case series study in 11 severe asthmatic patients, monthly adjustment of prednisone dose based on maintaining a PBE count below 300/μL reduced exacerbations, improved asthma control and reduced overall OCS use over 6 months. 51 Therefore, larger randomized studies examining PBE-based treatment adjustment algorithms across asthma severities are merited.
FeNO is a corticosteroid-responsive biomarker in all but the most severe corticosteroid-resistant forms of asthma (see above). Meta-analysis of clinical trials suggests that FeNO-based management strategies can significantly reduce exacerbation rate, although other clinical parameters such as lung function, ICS dose and symptoms were not reduced. 52 In sum, tailoring of anti-inflammatory ICS dose based on type 2 biomarkers such as FeNO and airway or blood eosinophils shows promise for the reduction of exacerbations in moderate-to-severe asthmatic patients, and further trials are required to validate these approaches.
TARGETED THERAPIES FOR CORTICOSTEROID-RESISTANT TYPE 2 SEVERE ASTHMA
A proportion of severe asthmatic patients have elevated type 2 biomarkers despite treatment with high-dose ICS or OCS. The development of novel therapies, predominantly monoclonal antibodies, targeting various mediators of type 2 inflammation holds significant promise for the treatment of corticosteroid-resistant type 2 asthma. Biomarkers are proving critical to the recent success of these agents in clinical trials and their transition to the clinic (Tables 1-3, Fig. 3 68, 69, 81 Of note, omalizumab may be efficacious in non-atopic severe asthma. 86 Indeed, omalizumab efficacy in non-atopic asthmatic patients with nasal polyps (typically associated with type 2 asthma) further supports a potential role for type 2 biomarkers in the identification of responsive patients. 87 Responsive biomarkers. Omalizumab treatment significantly reduces sputum and bronchial tissue eosinophils. 83 In addition, a recent clinical trial demonstrated that decreased serum IgE after commencement of omalizumab treatment associated with decreased exacerbation rate.
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IL-5 signalling antagonists
Mepolizumab, reslizumab and benralizumab
Mepolizumab and reslizumab are humanized monoclonal antibodies that bind IL-5, whilst benralizumab targets IL-5 receptor alpha, expressed on eosinophils and basophils, to inhibit IL-5 signalling. The development of mepolizumab is a pivotal example of the importance of biomarker-based stratification of responsive patients for targeted therapies. Although mepolizumab treatment suppressed blood and sputum eosinophil numbers, it failed to produce significant improvement in clinical end points in an initial trial in an unenriched population with moderate, persistent asthma. 53 Subsequent trials targeted severe eosinophilic asthma populations, demonstrating that mepolizumab can reduce frequency of asthma exacerbations, improve asthma symptoms and improve lung function. [55] [56] [57] [58] [59] Mepolizumab retains efficacy in the most severe, OCS-dependent eosinophilic asthma 88 allowing clinically relevant reductions in OCS dose. 56, 59 Reslizumab achieved similar success in severe eosinophilic asthma, reducing asthma exacerbation rate, improving lung function and statistically improving asthma control and quality of life-related metrics. 61 Both mepolizumab (USA, Europe, Canada, Japan and Australia) and reslizumab (USA, Europe and Canada) have been approved as an add-on maintenance treatment of patients with severe eosinophilic asthma. Phase 2 and 3 clinical trials have demonstrated the efficacy of benralizumab with improvements in exacerbations and lung function in uncontrolled moderate-to-severe eosinophilic asthma (Table 1) . [64] [65] [66] [67] Selection biomarkers. The first successful trials of mepolizumab and reslizumab in severe asthma selected patients based on the presence of sputum eosinophilia (>3%). 55, 56, 60 A subsequent mepolizumab trial recruited patients on the basis of eosinophilic inflammation defined by the presence of sputum eosinophilia (>3%), FeNO >50 ppb or PBE counts of over 300/μL. Surprisingly, subsequent analyses of this trial concluded that blood but not sputum eosinophilia correlated with clinical response. 57, 80 Further trials and analysis demonstrated that a PBE threshold of >150/μL at screening or a single measure >300/μL in the prior 12 months enriched a mepolizumab-responsive population. 58, 89 In contrast, higher PBE thresholds of >400 and >300/μL identify reslizumab-and benralizumabresponsive populations, respectively (Table 2) . 62, 63 The cut-off value of mepolizumab was determined from meta-analysis of trials involving 846 patients receiving drug. 89 Reslizumab trials may have not been sufficiently powered to detect efficacy at lower PBE thresholds, as most patients were recruited based on PBE >400/μL. Notably, the magnitude of exacerbation reduction achieved with mepolizumab appears greatest in those with the highest baseline PBE counts. 89 Additional type-2-related biomarkers such as serum IgE levels and atopy do not identify mepolizumab-responsive patients. 90 Responsive biomarkers. Mepolizumab and reslizumab reduce blood and sputum eosinophil counts. 53, [55] [56] [57] [58] [59] [60] [61] 91, 92 Benralizumab possesses an afucosylated oligosaccharide core and induces antibodymediated cell toxicity towards target cells, resulting in depletion of bone marrow and blood eosinophils to virtually undetectable levels and reductions in sputum eosinophils and blood eosinophils. 93 Persistence of eosinophilopoiesis in the airways in mepolizumabtreated individuals may result in variable sputum eosinophil depletion. 92 Of note, FeNO, often associated with systemic and airway eosinophilia, is unaffected by mepolizumab treatment (Table 3) . 55, 57 This finding is supportive of the notion that IL-5-related eosinophilia and IL-4/IL-13-related biomarkers including FeNO may represent mechanistically distinct phenotypes. The potential importance of this dichotomy is illustrated further by results from trials of IL-4/IL-13 antagonists (below).
Benralizumab significantly reduces eosinophil-related serum biomarkers eosinophilderived neurotoxin (EDN) and eosinophil cationic protein (ECP), whilst TNFα and interferon gamma (IFNγ) are unchanged. 82 Although indicative of biological response, further work is required to establish the predictive ability of these biomarkers for clinical response.
IL-4/IL-13 signalling antagonists Lebrikizumab and tralokinumab
Lebrikizumab and tralokinumab are monoclonal antibodies that bind to and neutralize IL-13. Recent replicate phase 3 clinical trials of lebrikizumab reported inconsistent effects on exacerbation rates, the primary efficacy end point. 72 Failure to enrich for a history of asthma exacerbations during study recruitment likely contributed to the low rate of exacerbations in the study and the lack of a consistent effect of lebrikizumab. 94 A phase 2b clinical trial of tralokinumab in frequently exacerbating severe asthma patients did not show a significant reduction in annual exacerbation rate nor improvement in asthma control, although lung function was significantly improved in the overall study population. 74 Selection biomarkers. Serum periostin has been the most consistent biomarker in terms of identifying patient subsets responsive to lebrikizumab and tralokinumab (Table 2) . 71, 72, 74, 84 Those patients combining high serum periostin (>50 ng/mL) with high PBE (>300/μL) showed the greatest response to lebrikizumab. 72 Elevated FeNO also shows some promise, albeit amongst clinical trial populations that were already stratified according to specific clinical features and biomarkers. 71, 72 Elevated serum levels of proposed type 2 biomarkers chemokine (C-C motif ) ligand (CCL) 13, CCL17, chitinase-3-like protein 1 (CHI3L1) (YKL-40) and carcinoembryonic antigen (CEA) did not predict beneficial response to lebrikizumab in mild-atopic asthmatic patients in an allergen challenge trial. 84 Dipeptidyl peptidase 4 (DPP-4) is induced by IL-13 in airway epithelial cells and high baseline serum DPP-4 was associated with additional improvements in lung function and asthma control with tralokinumab. 74 Sputum IL-13 also shows promise as a selection biomarker; however, serum periostin and DPP-4 may be preferable due to accessibility of samples. 73 Responsive biomarkers. Lebrikizumab treatment induces rapid and persistent suppression of FeNO, whilst periostin is significantly decreased at later time points.
71,72 CCL13, CCL17 and IgE but not YKL-40 and CEA are reduced in mild-atopic asthmatic patients after 12 weeks of lebrikizumab treatment (Table 3) . 84 PBE counts can increase in response to lebrikizumab and tralokinumab. [71] [72] [73] [74] Whether decreases in FeNO or periostin upon commencement of treatment predict a clinically useful response is yet to be established.
Dupilumab
Dupilumab is a monoclonal antibody that binds to IL-4 receptor α (IL-4Rα), preventing binding of type 2 cytokines IL-4 and IL-13 and associated signalling. Clinical trials in uncontrolled, moderate-to-severe asthma populations have demonstrated that dupilumab significantly reduces annual exacerbation rate, improves lung function and asthma control and reduces the 
proportion of patients who experience exacerbations upon stepwise withdrawal of LABA and ICS. 75, 76 Selection biomarkers. Similar to IL-13 antagonists, and in contrast to IL-5 antagonists, the presence of elevated PBE count does not predict response to dupilumab. 76 Post hoc analysis of this trial demonstrated that both periostin-high and -low subgroups benefit from dupilumab treatment with reduced exacerbation rate and lung function, although lung function improvement in periostin-low patients is not Green boxes indicate selection biomarkers associated with positive outcomes. Red boxes indicate selection biomarkers that did not identify responsive patients.
CCL, chemokine (C-C motif ) ligand; CEA, carcinoembryonic antigen; CRTH2, chemoattractant receptor homologous molecule expressed on Th2 cells; CXCR2, C-X-C chemokine receptor type 2; DPP-4, dipeptidyl peptidase 4; FeNO, fractional exhaled nitric oxide; IL-4Rα, IL-4 receptor α; IL-17Rα, IL-17 receptor α; PBE, peripheral blood eosinophil; YKL-40, chitinase-3-like protein 1 (CHI3L1). 78 Green boxes indicate biomarkers that were altered in response to treatment. Red boxes indicate biomarkers unaltered by treatment. CCL, chemokine (C-C motif ) ligand; CEA, carcinoembryonic antigen; CRTH2, chemoattractant receptor homologous molecule expressed on Th2 cells; CXCR2, C-X-C chemokine receptor type 2; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; FeNO, fractional exhaled nitric oxide; IFNγ, interferon gamma; IL-4Rα, IL-4 receptor α; SAA, serum amyloid A; YKL-40, chitinase-3-like protein 1 (CHI3L1).
significant. 47 Thus, a clear biomarker-based enrichment strategy for identification of dupilumab-responsive patients remains to be determined.
Responsive biomarkers. Dupilumab treatment significantly decreases FeNO irrespective of PBE count, consistent with IL-4/IL-13-induced NOS expression driving elevated FeNO in asthma. 75, 76 Similar to IL-13 antagonists, dupilumab treatment can cause an increase in PBE in a small portion of treated individuals, although PBE counts return towards baseline levels over longer treatment periods. 76 Dupilumab reduces serum CCL17, eotaxin-3 and IgE, whilst YKL-40 and CEA are not affected (similar to lebrikizumab), highlighting CCL17 and IgE as potential treatment response biomarkers in patients receiving IL-4/IL-13 antagonists (Table 3) . 75 
Fevipiprant
In a recent trial in moderate-to-severe eosinophilic asthma, fevipiprant, a CRTH2 (chemoattractant receptor homologous molecule expressed on Th2 cells) antagonist, improved patient-reported outcomes and lung function. 77 Fevipiprant reduced eosinophil numbers in sputum and the airway mucosa, whilst not affecting PBE count. Given the clear correlation between PBE and the efficacy of IL-5 antagonists in reducing asthma exacerbations, it will be of interest to see whether fevipiprant can reduce exacerbation rate in further trials.
NON-TYPE 2 SEVERE ASTHMA
On the basis of sputum profiling in large patient cohorts, approximately 50% of asthma patients lack evidence of sputum eosinophilia and in this respect could be considered as non-type 2 asthmatic patients. 29 Similarly, when severe asthmatic populations have been studied, estimates of the prevalence of non-type 2-related disease based on assessment of sputum eosinophils or FeNO and PBE varies from around 43% 95 to 55%. 96 It is likely that non-type 2 asthma includes more than one phenotype, and a major challenge going forward will be to identify novel cellular and molecular signatures and targets for treatment of non-type 2 severe asthma.
Neutrophil predominant inflammation
Across the spectrum of asthma severities, a portion of non-type 2 (or non-eosinophilic) asthmatic patients exhibit neutrophilic inflammation in sputum. Studies have reported similar levels of airway neutrophilia in mild and severe forms of asthma, whilst others have reported increased airway neutrophilia in severe asthma. [96] [97] [98] Cluster analysis in a large cohort revealed that sputum neutrophilia associates with the most severe forms of asthma. 99 Estimates of the prevalence of neutrophilic severe asthma based on sputum profiling vary (potentially in part due to different thresholds being applied in different studies) but values reported include 22% and 27%.
95,100
Neutrophil-targeting treatment strategies
Neutrophilic asthma is linked to increased corticosteroid resistance and distinct airway pathology and lung function compared with type 2 asthma, and a large proportion of asthma exacerbations are associated with elevated airway neutrophils. 49 These observations prompted the hypothesis that targeting neutrophilic inflammation in asthma might provide therapeutic benefit. Neutrophil recruitment to the airways of asthmatic patients is dependent on C-X-C chemokine receptor type 2 (CXCR2)-mediated signalling 101 ; however, a recent clinical trial of CXCR2 antagonist AZD5069 did not show clinical benefit in severe asthma. 78 Severe asthmatic patients were included in this trial on the basis of raised absolute blood neutrophil counts (>2700/μL) without elevated type 2 biomarkers (PBE >500/μL or serum IgE >750 kIU/L). However, given the poor predictive strength of blood neutrophils for elevated airway neutrophils, 30 it is possible that a responsive population may have been missed. Similarly, a clinical trial of brodalumab, a monoclonal antibody-based IL-17 receptor antagonist anticipated to inhibit neutrophilic inflammation, did not show any clinical benefit in a non-enriched moderate-to-severe asthma population (Tables 1,2) . 79 In sum, clinical trials with agents targeting neutrophil-related airway Omalizumab, which targets IgE, has recently been suggested to provide most clinical benefit in patients with elevated type 2 biomarkers including blood eosinophils, periostin and FeNO. Dupilumab has been reported to show clinical benefit in patients lacking elevated type 2 biomarkers, although further trials are required to fully establish and understand this observation. Of course, not all combinations of treatments and biomarkers have been explored or reported and the depicted asthma treatment biomarker network is in no way intended to be definitive.
inflammation have not supported the concept of neutrophilic inflammation as a treatable trait in severe asthma. However, it is not possible to exclude the possibility that these trials may have failed due to a lack of validated biomarkers for neutrophil predominant disease.
Biomarkers of neutrophil predominant inflammation
Classification of neutrophil predominant airway inflammation based on sputum cell count is unfeasible in the non-specialist clinic due to high technical and resource-related requirements. Whilst blood neutrophil percentage and blood neutrophil:lymphocyte ratio are increased in neutrophilic asthma, they are only weakly predictive of airway neutrophilia and are thus unlikely to be useful as surrogate biomarkers. 30 Neutrophilic asthma is associated with increased levels of sputum high mobility group box 1 (HMGB-1), 102 matrix metalloprotease (MMP)-9, 103 TNFα, TNF receptor (TNFR) I, TNFRII and IL-1β 98, 103 and a reduced ratio of galectin-3: galectin-3-binding protein. 104 Transcriptomic analysis of raw sputum samples identified a transcriptional signature relating to altered innate immune pathways in neutrophilic asthma including increased IL-1β and CXCR2. 105 Validated systemic biomarkers of airway neutrophilia in asthma are lacking, although candidate molecules have been identified. Airway neutrophilia is associated with increased expression of α-defensins 1, 1B, 3 and 4 and neutrophil proteases cathepsin and elastase in whole blood. 106 Altered DNA methylation profiles of blood monocytes and elevated plasma C-reactive protein (CRP) and IL-6 have also been proposed as potential systemic markers of airway neutrophilia in asthma. 107, 108 Further validation of these markers in larger cohorts and in severe asthma populations is required.
Asthma without overt airway inflammation
A proportion of people with asthma have a significant symptom burden despite the apparent absence of airway inflammation. In some such individuals, the high symptom scores may be driven by co-morbidities such as obesity, gastro-oesophageal reflux, anxiety and vocal cord dysfunction, rather than by 'asthma' per se. Management guidelines usually advocate identification and management of these conditions. 4 However, the evidence that managing these co-morbidities has a major clinical impact on asthma outcome in this population is limited.
On the basis of sputum studies, some investigators have defined an entity termed 'paucigranulocytic asthma', in which the proportions of sputum eosinophils and neutrophils are within the healthy range. 100 In both general and severe asthma populations, paucigranulocytic asthma occurs with similar frequency to eosinophilic asthma. 14, 109 Such individuals tend to have better spirometry than those with eosinophilic and neutrophilic asthma, a lower frequency of asthma exacerbations and relatively low FeNO.
14 A retrospective cross-sectional study of 833 asthmatic and 194 healthy subjects concluded that paucigranulocytic asthma was characterized by low-grade airway and systemic inflammation, as evidenced by significantly higher numbers of blood eosinophils, neutrophils and lymphocytes and elevated sputum eosinophils compared with healthy subjects.
14 This low level eosinophilic inflammation may explain why some paucigranulocytic asthmatic patients may still benefit from ICS therapy, and indeed elevated FeNO on a paucigranulocytic background could be predictive of ICS response. 39 Whether low-grade inflammation in severe paucigranulocytic asthma is an important therapeutically targetable trait remains to be established. Furthermore, whilst the paucigranulocytic phenotype is defined by lack of overt cellular inflammation of the airway lumen, molecular alterations may exist and this requires further characterization. 105 Of note, mucosal inflammation may occur in the absence of sputum inflammatory cells. 110 Sputum mast cells may be overlooked by some staining protocols, and T cells may be present in the airway mucosa but not in the airway lumen; hence, it is possible that these cells and others may contribute to disease expression in some cases of apparent paucigranulocytic asthma. Alternatively, it is possible in some people with asthma that disease expression is driven by inflammationindependent 'intrinsic' dysfunction of airway smooth muscle and nerves. One may speculate that such individuals might benefit from bronchial thermoplasty, although this is yet to be tested.
FUTURE DIRECTIONS
Having biomarkers that are readily accessible to practicing clinicians remains a challenge. Sputum induction and bronchoscopy are unlikely to become widely accessible outside specialist centres, so there is a focus on biomarkers in body fluids that can be more easily obtained such as blood, urine and exhaled breath. Increasing interest in the microbiome of the upper airway, lower airway and gastro-intestinal tract and its relationship to asthma pathogenesis may also reveal new therapeutic targets; there is now evidence that the airway microbiome may even predict responsiveness to ICS. 111 Technological advances including the various 'omics' will undoubtedly see further growth in the number of molecules identified as potential biomarkers in difficult-to-treat asthma. 112 Genetic polymorphisms will likely predict responsiveness to targeted therapies. However, the immunopathology of asthma is complex, and it seems naïve to expect that a single biomarker or single nucleotide polymorphism will provide sufficient information (in isolation) on which to build precision medicine. As discussed above, the combination of multiple biomarkers can provide useful prognostic information, over and above that provided by single biomarkers. 45 Hence, it seems likely that the future will see clusters of biomarkers identified in which the numerous upregulated and downregulated molecules seen in large patient cohorts undergo sophisticated bioinformatic analyses. Separating the 'wheat' from the 'chaff' will require validation through prospective studies of well-characterized patient cohorts, international collaborations and testing of new treatment algorithms.
CONCLUSIONS
While advances have been made in identifying biomarkers associated with severe type 2 inflammation, little progress has been made in identifying biomarkers for use in non-type 2 severe asthma. Amidst all the hype around biomarkers, it is worth highlighting that conventional clinical features remain very important in severe asthma. For example, one of the best predictors of future asthma exacerbations is a history of prior exacerbations. In the absence of such a history, type 2 biomarkers lose a substantial degree of their predictive capacity. 94 If future asthma biomarkers are to survive in the clinical 'toolbox', they will need to provide new and useful information that would not otherwise be available from a thorough clinical assessment. Lead for the Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK), which aims to further understand how biomarkers can be used to better phenotype patients with severe asthma and optimize and target treatment more effectively.
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